Cancer Immunology and Immunotherapy [recurso electrónico] / edited by Glenn Dranoff.
Tipo de material:
TextoSeries Current Topics in Microbiology and Immunology ; 344Editor: Berlin, Heidelberg : Springer Berlin Heidelberg, 2011Descripción: XIV, 306 p. online resourceTipo de contenido: text Tipo de medio: computer Tipo de portador: online resourceISBN: 9783642141362Tema(s): Medicine | Oncology | Immunology | Biomedicine | Cancer Research | ImmunologyFormatos físicos adicionales: Printed edition:: Sin títuloClasificación CDD: 614.5999 Clasificación LoC:RC261-271Recursos en línea: Libro electrónico
En: Springer eBooksResumen: The recent FDA approval of Provenge as the first therapeutic cancer vaccine together with the recent demonstration that Ipilimumab , a monoclonal antibody that blocks the negative immune checkpoint cytotoxic T lymphocyte associated antigen-4, prolongs patient survival are major achievements that usher in a new era of cancer immunotherapy. These “first-in-class” treatments reflect the substantive progress that basic and translational scientists have made towards understanding the mechanisms underlying protective tumor immunity in cancer patients Immunotherapies were first explored at the turn of the twentieth century, but the crafting of potent treatments required more detailed knowledge of how the immune system responds to cancer. Advances in genetic, cellular, and biochemical technologies have begun to yield this critical information, focusing attention on immune recognition, regulation, and escape. Indeed, the dynamic interplay of these processes in the tumor microenvironment is now recognized to play a decisive role in determining disease outcome. This volume highlights the rapid progress and breadth of research in cancer immunology, and provides a framework for anticipating many more clinical successes in cancer immunotherapy.
| Tipo de ítem | Biblioteca actual | Colección | Signatura | Copia número | Estado | Fecha de vencimiento | Código de barras |
|---|---|---|---|---|---|---|---|
| Libro Electrónico | Biblioteca Electrónica | Colección de Libros Electrónicos | RC261 -271 (Browse shelf(Abre debajo)) | 1 | No para préstamo | 374684-2001 |
Navegando Biblioteca Electrónica Estantes, Código de colección: Colección de Libros Electrónicos Cerrar el navegador de estanterías (Oculta el navegador de estanterías)
| RC261 -271 The Chemokine System in Experimental and Clinical Hematology | RC261 -271 Diverse Effects of Hypoxia on Tumor Progression | RC261 -271 Phosphoinositide 3-kinase in Health and Disease | RC261 -271 Cancer Immunology and Immunotherapy | RC261 -271 Phosphoinositide 3-kinase in Health and Disease | RC261 -271 NF-kB in Health and Disease | RC261 -271 Melanoma Development |
The recent FDA approval of Provenge as the first therapeutic cancer vaccine together with the recent demonstration that Ipilimumab , a monoclonal antibody that blocks the negative immune checkpoint cytotoxic T lymphocyte associated antigen-4, prolongs patient survival are major achievements that usher in a new era of cancer immunotherapy. These “first-in-class” treatments reflect the substantive progress that basic and translational scientists have made towards understanding the mechanisms underlying protective tumor immunity in cancer patients Immunotherapies were first explored at the turn of the twentieth century, but the crafting of potent treatments required more detailed knowledge of how the immune system responds to cancer. Advances in genetic, cellular, and biochemical technologies have begun to yield this critical information, focusing attention on immune recognition, regulation, and escape. Indeed, the dynamic interplay of these processes in the tumor microenvironment is now recognized to play a decisive role in determining disease outcome. This volume highlights the rapid progress and breadth of research in cancer immunology, and provides a framework for anticipating many more clinical successes in cancer immunotherapy.
19
